CV Risk Assessment in Diabetes Mellitus

Choose a study mode

Play Quiz
Study Flashcards
Spaced Repetition
Chat to Lesson

Podcast

Play an AI-generated podcast conversation about this lesson
Download our mobile app to listen on the go
Get App

Questions and Answers

What is the estimated increased risk of developing cardiovascular disease (CVD) in individuals with Type 2 Diabetes Mellitus (T2DM)?

  • No increased risk
  • Two to four-fold (correct)
  • Five to six-fold
  • One to two-fold

Which of the following is NOT a cardiovascular risk factor that should be assessed in individuals with diabetes?

  • Dyslipidemia
  • Hypertension
  • Anemia (correct)
  • Obesity/overweight

Which condition is essential to consider when assessing cardiovascular risk in individuals with T2DM?

  • Presence of a family pet
  • Severe target-organ damage (correct)
  • Orthopedic disorders
  • Mental health history

What should be systematically assessed at least annually in all people with diabetes?

<p>Cardiovascular risk factors (A)</p> Signup and view all the answers

Which of the following indicates the most severe form of target-organ damage (TOD) related to diabetic complications?

<p>Presence of microvascular disease in at least three different sites (C)</p> Signup and view all the answers

What type of therapy is recommended for patients with T2D to help mitigate ASCVD risk?

<p>High-intensity statin therapy (C)</p> Signup and view all the answers

What is the purpose of the SCORE2-Diabetes algorithm?

<p>To estimate 10-year cardiovascular disease risk (A)</p> Signup and view all the answers

Which of the following factors is NOT integrated into the SCORE2-Diabetes risk estimation?

<p>Family medical history (D)</p> Signup and view all the answers

What does a coronary artery calcium (CAC) score of >100 Agatston units indicate?

<p>High CVD risk (B)</p> Signup and view all the answers

Which blood pressure medication class is recommended for T2D patients regardless of blood pressure levels?

<p>ACE inhibitors / ARBs (B)</p> Signup and view all the answers

Which of the following assessments is associated with increased risk of CVD events?

<p>Arterial stiffness assessed by pulse wave velocity (A)</p> Signup and view all the answers

What are the two drug classes recommended for CVD reduction in individuals with T2D?

<p>SGLT2 inhibitors and GLP-1 receptor agonists (A)</p> Signup and view all the answers

Which of the following is NOT a component of the ASCVD risk calculator, Risk Estimator Plus?

<p>Presence of kidney disease (A)</p> Signup and view all the answers

What is a key recommendation for managing weight in patients with diabetes and cardiovascular disease?

<p>Regular physical activity (A)</p> Signup and view all the answers

What screening method is recommended for assessing chronic kidney disease in individuals with type 2 diabetes?

<p>Urine albumin to creatinine ratio testing (C)</p> Signup and view all the answers

Which treatment is cited as a kidney-protective therapy for patients with type 2 diabetes and chronic kidney disease?

<p>Sodium-glucose cotransporter 2 inhibitors (B)</p> Signup and view all the answers

What is the primary recommendation for glycemic control in individuals with an eGFR greater than 15 mL/min per 1.73 m2?

<p>GLP-1 receptor agonists (B)</p> Signup and view all the answers

What is the recommended approach to smoking cessation in patients with both diabetes and cardiovascular disease?

<p>Using nicotine replacement therapies (D)</p> Signup and view all the answers

What is a significant cardiovascular risk factor in patients with diabetes?

<p>Poor glycemic control (B)</p> Signup and view all the answers

How prevalent is chronic kidney disease among individuals with type 2 diabetes?

<p>30% to 40% (B)</p> Signup and view all the answers

What is indicated for those with chronic kidney disease who have an eGFR of 30 mg/g?

<p>SGLT2 inhibitors (C)</p> Signup and view all the answers

Signup and view all the answers

Flashcards

CV Risk in Diabetes

Individuals with type 2 diabetes are at a significantly increased risk of developing cardiovascular disease (CVD) during their lifetime, compared to those without diabetes.

ASCVD in Diabetes

Atherosclerotic cardiovascular disease (ASCVD) includes conditions like coronary artery disease, stroke, heart failure, and atrial fibrillation. It's a major concern for people with diabetes.

Impact of CV Disease on Prognosis

Having both diabetes and cardiovascular disease, particularly at a younger age, significantly impacts a person's long-term health outlook (prognosis).

Screening for Diabetes and CV Risk

Patients with cardiovascular disease (CVD) should be screened for diabetes, and those with diabetes should be assessed for cardiovascular risk factors.

Signup and view all the flashcards

Severe Target-Organ Damage (TOD)

Severe target-organ damage (TOD) is a marker of advanced cardiovascular disease in diabetics. It can involve multiple organs like the kidneys and eyes.

Signup and view all the flashcards

ASCVD Therapies in T2D

A diagnosis of type 2 diabetes (T2D) requires adjustments to cardiovascular disease (ASCVD) risk mitigation therapies due to increased risk in individuals with T2D. This includes more aggressive approaches like high-intensity statins and non-statin cholesterol-lowering drugs, with stricter LDL cholesterol targets.

Signup and view all the flashcards

ACE Inhibitors/ARBs in T2D

Beyond standard blood pressure (BP) management, ACE inhibitors or ARBs (angiotensin receptor blockers) are recommended even if BP is within normal limits. There may also be a need for more aggressive BP lowering targets in individuals with T2D to help reduce ASCVD risk.

Signup and view all the flashcards

SGLT2i & GLP-1 RA for T2D

To help prevent cardiovascular disease in individuals with T2D, the European Society of Cardiology (ESC) recommends using both a sodium glucose co-transporter 2 inhibitor (SGLT2i) and a glucagon-like peptide-1 receptor agonist (GLP-1 RA). This recommendation is based on numerous studies demonstrating the effectiveness of these medications in reducing cardiovascular risk.

Signup and view all the flashcards

SCORE2-Diabetes

SCORE2-Diabetes is a tool used to estimate the 10-year risk of developing CVD in patients with T2D who are aged 40 years or older, do not have existing ASCVD, and do not have severe kidney disease.

Signup and view all the flashcards

SCORE2-Diabetes Factors

The SCORE2-Diabetes algorithm considers traditional CVD risk factors (age, smoking, blood pressure, cholesterol) and adds diabetes-specific factors like age at diabetes diagnosis, HbA1c, and estimated glomerular filtration rate (eGFR). It provides risk estimates tailored to different geographical regions based on CVD prevalence.

Signup and view all the flashcards

CAC Scoring for CVD Risk

Coronary artery calcium (CAC) scoring can improve CVD risk prediction and reclassify risk when combined with conventional risk factor assessment. A CAC score of >100 Agatston units or ≥75th percentile for age, sex, and ethnicity suggests a higher risk for CVD.

Signup and view all the flashcards

Carotid & Femoral Plaque

Plaque buildup in the carotid arteries (which supply blood to the brain) or femoral arteries (in the legs) can also be used to improve CVD risk prediction.

Signup and view all the flashcards

Arterial Stiffness & PWV

Arterial stiffness is a marker for increased risk of CVD events. Pulse wave velocity (PWV) is a measurement used to assess arterial stiffness. Higher PWV suggests stiffer arteries and an increased risk of heart disease.

Signup and view all the flashcards

Diabetes and CKD: Risk & Screening

Individuals with type 2 diabetes are at a higher risk of developing chronic kidney disease (CKD), with approximately 30-40% experiencing it. The 2023 ESC guidelines strongly recommend routine screening for CKD in this patient group.

Signup and view all the flashcards

CKD Screening Tools

The 2022 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend using the CKD-Epidemiology Collaboration formula to calculate estimated glomerular filtration rate (eGFR) and assessing urine albumin-to-creatinine ratio for routine CKD screening.

Signup and view all the flashcards

Kidney Protection: 3 Pillars

SGLT2 inhibitors, ACE inhibitors/ARBs, and finerenone are considered the cornerstone of kidney-protective therapies for individuals with type 2 diabetes and CKD. This combination is backed by strong evidence.

Signup and view all the flashcards

SGLT2i in CKD

SGLT2 inhibitors are recommended for patients with CKD with an eGFR above 30 mg/g and above 20 mL/min per 1.73 m (Class I A recommendation in the 2023 ESC guidelines).

Signup and view all the flashcards

GLP-1 RAs in CKD

GLP-1 receptor agonists (GLP-1 RAs) are recommended for achieving adequate glycemic control in individuals with an eGFR greater than 15 mL/min per 1.73 m (Class I A recommendation in the 2023 ESC guidelines).

Signup and view all the flashcards

Glycemic Control in CKD

Good blood sugar control is an important aspect of managing diabetes and CKD. Achieving target glucose levels reduces the risk of complications in patients with both conditions.

Signup and view all the flashcards

Managing Diabetes and CKD

Individuals with diabetes and CKD need to be proactive in managing both conditions. This includes regular checkups, medication adherence, and lifestyle modifications to reduce further kidney damage.

Signup and view all the flashcards

Early Detection & Management

Early detection and management of diabetes and CKD are crucial for improving patient outcomes. Careful monitoring and appropriate interventions can help slow the progression of kidney disease and reduce complications.

Signup and view all the flashcards

Study Notes

CV Risk Assessment in DM

  • Individuals with type 2 diabetes mellitus (T2DM) have a significantly higher risk (two- to four-fold) of developing cardiovascular disease (CVD) throughout their lifetime.
  • This risk is alongside other CVD manifestations including coronary artery disease (CAD), stroke, heart failure (HF), atrial fibrillation (AF), and peripheral artery disease (PAD).
  • Many patients with CVD have undiagnosed T2DM.
  • Diabetes and CVD, especially at a younger age, significantly impacts prognosis.
  • Screening for diabetes in CVD patients & assessing CV risk in diabetes patients is crucial to evaluating them for CVD and kidney disease.

Risk Factors Assessment

  • For both atherosclerotic cardiovascular disease (ASCVD) prevention and heart failure management, cardiovascular risk factors must be assessed at least annually in all people with diabetes.
  • These factors involve the duration of diabetes, obesity/overweight, high blood pressure (hypertension), dyslipidemia (lipid disorders), smoking, family history of premature coronary disease, chronic kidney disease (CKD), and albuminuria.

Assessing CV Risk in T2DM

  • When assessing CV risk in individuals with T2DM, consider medical and family history, symptoms, examination findings, laboratory tests, and other diagnostic results.
  • Evaluate for the presence of ASCVD (atherosclerotic CVD or severe target-organ damage (TOD)).

Severe TOD

  • Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m² irrespective of albuminuria
  • eGFR 45-59 mL/min/1.73 m² with microalbuminuria (UACR 30–300 mg/g). Stage A2
  • Proteinuria (UACR >300 mg/g). Stage A3
  • Presence of microvascular disease in at least three different places (e.g., microalbuminuria (stage A2) with retinopathy and neuropathy).

ASCVD Risk-mitigating Therapies

  • High-intensity statin therapy and non-statin LDL cholesterol-lowering therapies, with aggressive LDL cholesterol targets.
  • ACE inhibitors/ARBs, independent of blood pressure (BP) consideration, & aggressive systolic BP targets.
  • Healthy lifestyle counseling, emphasizing physical activity engagement, healthy diet, weight management, and smoking abstinence.
  • Prescription of sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to reduce CVD in patients with T2DM or high risk for ASCVD.
  • Data from randomized controlled trials supports this approach.

SCORE2-Diabetes

  • Patients aged ≥40 years with T2DM without ASCVD or severe TOD, are recommended to use the SCORE2-Diabetes algorithm to estimate 10-year CVD risk.
  • SCORE2-Diabetes integrates conventional CVD risk factors (age, smoking status, systolic blood pressure, total/HDL cholesterol) with diabetes-specific information (diabetes diagnosis age, HbA1c, eGFR).
  • The model is calibrated for different CVD risk levels (low, moderate, high, very high) across various countries.

Cardiovascular Risk Categories in Type 2 Diabetes

  • Categorizing cardiovascular risks provides clinicians with a framework to assess treatment strategies.
  • Categories defined by 10-year CVD risk using SCORE2-Diabetes, in relation to the presence of clinically established ASCVD or severe TOD.

Recommendations to Assess Cardiovascular Risk

  • Screen patients with diabetes for severe TOD.
  • Assess medical history and symptoms suggestive of ASCVD in patients with diabetes.
  • Estimate 10-year CVD risk in patients with T2DM without symptomatic ASCVD or severe TOD using SCORE2-Diabetes
  • Specific guidelines and classifications, represented by classes and levels, are suggested.

American College of Cardiology ASCVD Risk Calculator

  • The Risk Estimator is a tool to calculate the 10-year CVD risk of first ASCVD events.

Improving CVD Risk Prediction

  • Coronary artery calcium (CAC) scoring enhances CVD risk prediction and reclassifies risk when integrated with conventional risk factors.
  • A CAC score >100 Agatston units or ≥75th percentile for age, sex, and ethnicity favours up-classification of CVD risk.

Updates in the Management of CVD and DM

  • Update recommendations to address cardiovascular risk in people with type 2 diabetes.
  • Include assessment of systematic risk using SCORE2-Diabetes.
  • Measurement of blood pressure to control hypertension
  • Using glucose-lowering medicines such as SGLT2i and GLP-1 receptor agonists for improved results and reduced risks when appropriate.
  • Screen for atrial fibrillation and monitor complications related to diabetes (ASCVD, CKD, HF).
  • Recommendations on weight reduction, healthy diet, smoking cessation, physical activity, and glycemic control in the management of CVD in diabetes.

CVD Risk Reduction

  • The management of risks and treatments related to CVD in the context of diabetes.
  • The diagram shows various factors involved in cardiovascular risk, including weight, physical activity, diet, nutrients, glycemic targets,, and smoking cessation.

Recommendation for Reducing Weight

  • Recommendations to encourage weight reduction in people with diabetes mellitus (DM) and cardiovascular disease (CVD). Emphasis on lifestyle changes (physical exertion and improved weight control) with or without medical interventions.

Recommendation for Nutrition

  • Recommendations for dietary practices in the management of individuals with diabetes and CVD, notably suggesting the Mediterranean or plant-based diet.
  • High emphasis on unsaturated fats to reduce cardiovascular risk.

Recommendations for Physical Activity

  • Recommendations to increase physical activity in patients with type 2 diabetes and cardiovascular disease or not.
  • Focus on endurance training and possible adjustments tailored to existing comorbidities.

Recommendation for Smoking Cessation

  • Recommendations for smoking cessation to reduce cardiovascular risk in individuals with diabetes and CVD.
  • Include therapies like nicotine replacement, counseling or other treatment options.

Recommendation for Glycemic Targets

  • Importance of tight glycemic control using HbA1c(<7%) to minimize the risks of microvascular complications with diabetes in the management of cardiovascular disease.
  • Individualization of targets based on comorbidities, life expectancy, and duration of diabetes.

Risk Assessment for T2DM

  • Risk assessment based on the presence of ASCVD/severe target-organ damage (TOD) and 10-year CVD risk estimation via SCORE2-Diabetes helps further guide treatment recommendations for different risk levels (low, moderate, high, and very high).

Glucose-Lowering Medications

  • Prioritizing glucose-lowering agents with proven cardiovascular (CV) benefits (e.g., SGLT-2 inhibitors and GLP-1 receptor agonists), over agents without such proof, in the management of T2DM & ASCVD.

Other Glucose-Lowering

  • Metformin & pioglitazone are potential options when additional glucose control is necessary for patients with T2DM and ASCVD or those without HF, respectively.

Diabetes and Chronic Kidney Disease

  • Approximately 30-40% of people with T2DM develop chronic kidney disease (CKD).
  • Guidelines promote screening strategies for CKD in individuals with T2DM, emphasizing routine eGFR measurement and urine albumin-to-creatinine ratio testing.

Kidney-Protective Effects of SGLT2is

  • SGLT2 inhibitors, along with ACE inhibitors/ARBs and finerenone, are integral in evidence-based kidney protection for T2DM and CKD patients.
  • GLP-1 RAs are recommended for suitable glycemic control in individuals with eGFR above 15 mL/min per 1.73 m², as evidenced in the 2023 guidelines.

Studying That Suits You

Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

Quiz Team

Related Documents

CV Risk Assessment in DM PDF

More Like This

Inclisiran in Patients at High Cardiovascular Risk Quiz
12 questions
Cardiovascular Risk Management
10 questions

Cardiovascular Risk Management

TrustingHurdyGurdy7664 avatar
TrustingHurdyGurdy7664
Use Quizgecko on...
Browser
Browser